ArticleThe Indian journal of medical research2025
Prognostic significance of baseline serum ferritin in newly diagnosed multiple myeloma cases: A retrospective study from southern India.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding metabolic dysfunction in cancer: foundations for early detection and personalized therapeutics.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Ferritin levels, crucial for iron homeostasis, may hold prognostic significance in multiple myeloma (MM) due to their responsiveness to inflammation. The objective of this study was to evaluate the prognostic significance of baseline serum ferritin levels in predicting progression-free survival (PFS) and overall survival (OS) in newly diagnosed south Indian patients with multiple myeloma. Methods We retrospectively analysed records of 152 newly diagnosed multiple myeloma (NDMM) patients, grouping them by ferritin levels: group 1 with low ferritin (LF) (<300 ng/ml, n=68) and group 2 with high ferritin (HF) (≥300 ng/ml, n=84). Cox Proportional Hazard Models were used to identify prognostic risk factors for PFS and OS. Results NDMM patients with elevated diagnostic ferritin levels exhibited significantly higher levels of creatinine (P=<0.0001), lactate dehydrogenase (LDH, P=0.005), C-reactive protein (CRP, P=0.02), erythrocyte sedimentation rate (ESR, P=0.04), rate of disease progression (P=0.002), and death (P=0.011), along with a notable decrease in albumin (P=<0.0001) and haemoglobin (P=0.04) compared to MM patients with low ferritin levels. Time-to-event analysis revealed shorter PFS (P=0.0053) and OS (P=0.014) in the HF group. Elevated ferritin independently predicted progression [HR=2.59, 95% confidence interval (CI): 1.29-5.16, P=0.006] and was associated with increased mortality risk (HR=2.93, 95% CI: 1.19-7.24, P=0.02). Hazard ratios for progression and mortality increased with an increase in ferritin levels. Ferritin showed a weak positive correlation with plasma cell per cent (r=0.122, 95% CI: -0.07-0.31). Ferritin also provided better prediction (25.8 and 32.4%) of PFS and OS than CRP (14.7 and 15.8%). Interpretation & conclusions High ferritin levels in multiple myeloma are linked to worse prognosis and poor outcomes, highlighting the need for further research to validate and expand these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.